-DOCSTART-	O

Title	O
:	O
Introduction	O
of	O
a	B-I
Management	I-I
Toolkit	I-I
for	O
Lewy	O
Body	O
Dementia	O
:	O
A	O
Pilot	O
Cluster	O
-	O
Randomized	O
Trial	O
.	O

METHODS	O
:	O
We	O
randomized	O
23	O
memory	O
/	O
dementia	O
,	O
movement	O
disorder	O
,	O
or	O
nonspecialist	O
secondary	O
care	O
services	O
to	O
the	B-I
management	I-I
toolkit	I-I
or	O
usual	B-C
care	I-C
.	O

People	B-P
with	I-P
dementia	I-P
with	I-P
Lewy	I-P
bodies	I-P
or	I-P
Parkinson	I-P
'	I-P
s	I-P
disease	I-P
dementia	I-P
underwent	I-P
assessments	I-P
of	I-P
cognition	I-P
,	I-P
motor	I-P
and	I-P
neuropsychiatric	I-P
symptoms	I-P
,	I-P
and	I-P
global	I-P
outcome	I-P
at	I-P
baseline	I-P
and	I-P
3	I-P
and	I-P
6	I-P
months	I-P
.	O

Healthcare	B-O
,	O
personal	B-O
and	O
social	B-O
care	I-O
costs	I-O
,	O
and	O
carer	B-O
-	I-O
related	I-O
outcomes	I-O
of	I-O
carer	I-O
stress	I-O
,	O
depression	B-O
,	O
and	O
anxiety	B-O
were	O
also	O
examined	O
.	O

-DOCSTART-	O

Title	O
:	O
One	O
call	O
makes	O
a	O
difference	O
:	O
An	O
evaluation	O
of	O
the	B-I
Alzheimer	I-I
'	I-I
s	I-I
Association	I-I
National	I-I
Helpline	I-I
on	O
dementia	B-P
caregiver	I-P
outcomes	O
.	O

METHODS	O
:	O
Four	B-P
hundred	I-P
and	I-P
forty	I-P
-	I-P
five	I-P
non	I-P
-	I-P
crisis	I-P
callers	I-P
were	O
randomly	O
assigned	O
to	O
the	B-C
traditional	I-C
Helpline	I-C
"	I-C
Care	I-C
Consultation	I-C
"	I-C
or	O
a	B-I
"	I-I
Care	I-I
Consultation	I-I
Plus	I-I
"	I-I
condition	I-I
that	O
included	O
one	O
additional	O
booster	O
call	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
long	B-I
-	I-I
term	I-I
omega	I-I
-	I-I
3	I-I
supplementation	I-I
and	O
a	B-I
lifestyle	I-I
multidomain	I-I
intervention	I-I
on	O
intrinsic	O
capacity	O
among	O
community	B-P
-	I-P
dwelling	I-P
older	I-P
adults	I-P
:	O
Secondary	O
analysis	O
of	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
(	O
MAPT	O
study	O
)	O
.	O

METHODS	O
:	O
Secondary	O
analysis	O
from	O
the	O
factorial	O
-	O
design	O
3	O
-	O
year	O
Multidomain	O
Alzheimer	O
Preventive	O
Trial	O
(	O
MAPT	O
)	O
with	O
1445	B-P
subjects	I-P
(	I-P
64	I-P
.	I-P
2	I-P
%	I-P
female	I-P
,	I-P
mean	I-P
age	I-P
75	I-P
.	I-P
3	I-P
years	I-P
,	I-P
SD	I-P
=	I-P
4	I-P
.	I-P
4	I-P
)	I-P
randomized	O
to	O
one	O
group	O
of	O
MI	B-I
plus	O
?	B-I
-	I-I
3	I-I
(	O
800	B-I
mg	I-I
docosahexaenoic	I-I
acid	I-I
and	O
225	B-I
mg	I-I
eicosapentaenoic	I-I
acid	I-I
/	O
day	O
)	O
;	O
MI	B-I
plus	O
placebo	B-C
;	O
?	B-I
-	I-I
3	I-I
supplementation	I-I
alone	O
;	O
or	O
placebo	B-C
alone	I-C
.	O

Data	O
collection	O
was	O
held	O
between	O
2008	O
and	O
2014	O
.	O

IC	B-O
domains	I-O
were	O
examined	O
with	O
the	B-O
Geriatric	I-O
Depression	I-O
Scale	I-O
(	O
psychological	B-O
)	O
;	O
Short	B-O
Physical	I-O
Performance	I-O
Battery	I-O
(	O
mobility	B-O
)	O
;	O
Z	B-O
-	I-O
score	I-O
combining	I-O
four	I-O
tests	I-O
(	O
cognitive	B-O
function	I-O
)	O
;	O
and	O
handgrip	B-O
strength	I-O
(	O
vitality	B-O
)	O
.	O

All	O
domains	O
were	O
combined	O
into	O
a	O
composite	O
IC	O
Z	O
-	O
score	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
Cognition	O
and	O
Flow	O
Study	O
:	O
A	O
Feasibility	O
Randomized	O
Controlled	O
Trial	O
of	O
the	O
Effects	O
of	O
Cognitive	B-I
Training	I-I
on	O
Cerebral	O
Blood	O
Flow	O
.	O

METHODS	O
:	O
Twenty	B-P
HG	I-P
,	I-P
24	I-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
(	I-P
AD	I-P
)	I-P
,	I-P
and	I-P
12	I-P
with	I-P
MCI	I-P
were	O
randomized	O
to	O
12	O
weeks	O
of	O
multi	B-I
-	I-I
domain	I-I
CT	I-I
or	O
control	O
.	O

Outcomes	O
included	O
:	O
cognition	B-O
(	O
Addenbrooke	B-O
'	I-O
s	I-O
Cognitive	I-O
Examination	I-O
III	I-O
)	O
,	O
mood	B-O
,	O
quality	B-O
of	I-O
life	I-O
(	I-O
QoL	I-O
)	I-O
,	O
physical	B-O
,	O
and	O
neurovascular	B-O
function	I-O
(	O
transcranial	B-O
Doppler	I-O
ultrasonography	I-O
measured	I-O
task	I-O
activation	I-O
of	I-O
CBFv	I-O
responses	I-O
)	O
.	O

Data	O
are	O
presented	O
as	O
mean	O
difference	O
(	O
MD	O
)	O
and	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
,	O
pharmacokinetics	O
and	O
exploratory	O
pro	O
-	O
cognitive	O
effects	O
of	O
HTL0018318	B-I
,	O
a	B-I
selective	I-I
M	I-I
1	I-I
receptor	I-I
agonist	I-I
,	O
in	O
healthy	B-P
younger	I-P
adult	I-P
and	I-P
elderly	I-P
subjects	I-P
:	O
a	O
multiple	O
ascending	O
dose	O
study	O
.	O

METHODS	O
:	O
This	O
randomised	O
,	O
double	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
was	O
performed	O
,	O
investigating	O
oral	B-I
doses	I-I
of	I-I
15	I-I
-	I-I
35	I-I
mg	I-I
/	I-I
day	I-I
HTL0018318	I-I
or	O
placebo	B-C
in	O
7	B-P
cohorts	I-P
of	I-P
healthy	I-P
younger	I-P
adult	I-P
(	I-P
n	I-P
=	I-P
36	I-P
;	I-P
3	I-P
cohorts	I-P
)	I-P
and	I-P
elderly	I-P
(	I-P
n	I-P
=	I-P
50	I-P
;	I-P
4	I-P
cohorts	I-P
)	I-P
subjects	I-P
.	O

Safety	B-O
,	O
tolerability	B-O
and	O
pharmacokinetic	B-O
measurements	I-O
were	O
performed	O
.	O

Pharmacodynamics	O
were	O
assessed	O
using	O
a	B-O
battery	I-O
of	I-O
neurocognitive	I-O
tasks	I-O
and	O
electrophysiological	B-O
biomarkers	I-O
of	I-O
synaptic	I-O
and	O
cognitive	B-O
functions	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Interventional	O
Study	O
to	O
Evaluate	O
the	O
Clinical	O
Effects	O
and	O
Safety	O
of	O
the	B-I
Nutraceutical	I-I
Compound	I-I
BrainUp	I-I
-	I-I
10	I-I
in	O
a	B-P
Cohort	I-P
of	I-P
Patients	I-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
:	O
A	O
Multicenter	O
,	O
Randomized	O
,	O
Double	O
-	O
Blind	O
,	O
and	O
Placebo	O
-	O
Controlled	O
Trial	O
.	O

METHODS	O
:	O
The	O
was	O
a	O
multicenter	O
,	O
randomized	O
,	O
double	O
blind	O
,	O
placebo	O
-	O
controlled	O
phase	O
II	O
clinical	O
study	O
in	O
mild	B-P
to	I-P
moderate	I-P
AD	I-P
patients	I-P
treated	O
with	O
BrainUp	B-I
-	I-I
10	I-I
daily	O
,	O
while	O
controls	O
received	O
a	B-C
placebo	I-C
.	O

Primary	O
endpoint	O
was	O
Apathy	B-O
(	O
AES	B-O
scale	I-O
)	O
,	O
while	O
secondary	O
endpoints	O
included	O
Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
,	O
Trail	B-O
Making	I-O
Test	I-O
(	O
TMT	B-O
A	I-O
and	O
TMT	B-O
B	I-O
)	O
,	O
and	O
Neuropsychiatry	B-O
Index	I-O
(	I-O
NPI	I-O
)	I-O
.	O

AD	O
blood	O
biomarkers	O
were	O
analyzed	O
.	O

Laboratory	O
tests	O
were	O
applied	O
to	O
all	O
subjects	O
.	O

-DOCSTART-	O

Title	O
:	O
Learning	B-I
to	I-I
play	I-I
golf	I-I
for	O
elderly	B-P
people	I-P
with	I-P
subjective	I-P
memory	I-P
complaints	I-P
:	O
feasibility	O
of	O
a	O
single	O
-	O
blinded	O
randomized	O
pilot	O
trial	O
.	O

METHODS	O
:	O
In	O
a	O
22	O
-	O
week	O
single	O
-	O
blinded	O
randomized	O
controlled	O
trial	O
,	O
elderly	B-P
people	I-P
with	I-P
SMC	I-P
were	O
allocated	O
to	O
the	B-I
golf	I-I
(	O
n	O
=	O
25	O
,	O
180	O
min	O
training	O
/	O
week	O
)	O
or	O
control	O
group	O
(	O
n	O
=	O
21	O
)	O
.	O

Primary	O
outcomes	O
were	O
feasibility	B-O
(	O
golf	B-O
exam	I-O
,	O
adherence	B-O
,	O
adverse	B-O
events	I-O
)	O
and	O
general	B-O
cognitive	I-O
function	I-O
(	O
Alzheimer	B-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
)	O
.	O

Secondary	O
outcomes	O
include	O
specific	B-O
cognitive	I-O
functions	I-O
(	O
Response	B-O
Inhibition	I-O
,	O
Corsi	B-O
Block	I-O
Tapping	I-O
Test	I-O
,	O
Trail	B-O
Making	I-O
Test	I-O
)	O
,	O
KP	B-O
metabolites	I-O
and	O
physical	B-O
performance	I-O
(	O
6	B-O
-	I-O
Minute	I-O
-	I-O
Walk	I-O
-	I-O
Test	I-O
)	O
.	O

Baseline	O
-	O
adjusted	O
Analysis	O
-	O
of	O
-	O
Covariance	O
was	O
conducted	O
for	O
each	O
outcome	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
Folic	B-I
Acid	I-I
and	O
Vitamin	B-I
B12	I-I
Supplementation	I-I
on	O
Cognitive	O
Impairment	O
and	O
Inflammation	O
in	O
Patients	B-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
:	O
A	O
Randomized	O
,	O
Single	O
-	O
Blinded	O
,	O
Placebo	O
-	O
Controlled	O
Trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
randomized	O
,	O
single	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

Patients	B-P
(	I-P
n=120	I-P
)	I-P
diagnosed	I-P
clinically	I-P
as	I-P
probable	I-P
AD	I-P
and	I-P
in	I-P
stable	I-P
condition	I-P
from	I-P
Tianjin	I-P
Key	I-P
Laboratory	I-P
of	I-P
Cerebrovascular	I-P
and	I-P
Neurodegenerative	I-P
Diseases	I-P
.	O

Individuals	O
were	O
randomly	O
divided	O
into	O
the	O
intervention	O
group	O
(	O
n=60	O
,	O
folic	B-I
acid	I-I
1	O
.	O
2	O
mg	O
/	O
d	O
+	O
vitamin	B-I
B12	I-I
50	O
?g	O
/	O
d	O
)	O
and	O
the	B-C
placebo	I-C
group	O
(	O
n=60	O
)	O
.	O

Cognitive	B-O
performance	I-O
,	O
blood	B-O
folate	I-O
,	O
vitamin	B-O
B12	I-O
,	O
one	B-O
carbon	I-O
cycle	I-O
metabolite	I-O
,	O
and	O
inflammatory	B-O
cytokine	I-O
levels	I-O
were	O
measured	O
at	O
baseline	O
and	O
after	O
6	O
months	O
.	O

The	O
data	O
were	O
analyzed	O
using	O
linear	O
mixed	O
models	O
for	O
repeated	O
measures	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
tablet	B-I
huperzine	I-I
-	I-I
A	I-I
on	O
memory	O
,	O
cognition	O
,	O
and	O
behavior	O
in	O
Alzheimer	O
'	O
s	O
disease	O
.	O

METHODS	O
:	O
Using	O
multicenter	O
,	O
prospective	O
,	O
double	O
-	O
blind	O
,	O
parallel	O
,	O
placebo	O
controlled	O
and	O
randomized	O
method	O
,	O
50	B-P
patients	I-P
were	O
administered	O
orally	O
0	B-I
.	I-I
2	I-I
mg	I-I
(	I-I
4	I-I
tablets	I-I
)	I-I
Hup	I-I
and	O
53	O
patients	O
were	O
given	O
po	B-C
4	I-C
tablets	I-C
of	I-C
placebo	I-C
bid	O
for	O
8	O
wk	O
.	O

All	O
patients	O
were	O
evaluated	O
with	O
Wechsler	B-O
memory	I-O
scale	I-O
,	O
Hasegawa	B-O
dementia	I-O
scale	I-O
,	O
mini	B-O
-	I-O
mental	I-O
state	I-O
examination	I-O
scale	I-O
,	O
activity	B-O
of	I-O
daily	I-O
living	I-O
scale	I-O
,	O
treatment	B-O
emergency	I-O
symptom	I-O
scale	I-O
,	O
and	O
measured	O
with	O
BP	B-O
,	O
HR	B-O
,	O
ECG	B-O
,	O
EEG	B-O
,	O
ALT	B-O
,	O
AKP	B-O
,	O
BUN	B-O
,	O
Cr	B-O
,	O
Hb	B-O
,	O
WBC	B-O
,	O
and	O
urine	B-O
routine	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Relationship	O
between	O
pharmacodynamic	O
activity	O
and	O
cognitive	O
effects	O
of	O
eptastigmine	B-I
in	O
patients	B-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

Eptastigmine	O
Study	O
Group	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
unbalanced	O
parallel	O
-	O
group	O
study	O
.	O

One	B-P
-	I-P
hundred	I-P
and	I-P
three	I-P
patients	I-P
(	O
83	O
in	O
the	B-I
eptastigmine	I-I
group	O
and	O
20	O
in	O
the	B-C
placebo	I-C
group	O
)	O
were	O
recruited	O
by	O
10	O
centers	O
.	O

Patients	O
received	O
20	B-I
mg	I-I
eptastigmine	I-I
or	O
placebo	B-C
for	O
4	O
weeks	O
with	O
twice	O
-	O
a	O
-	O
day	O
or	O
three	O
-	O
times	O
-	O
a	O
-	O
day	O
regimens	O
,	O
depending	O
on	O
body	O
weight	O
(	O
<	O
or	O
=	O
65	O
kg	O
or	O
>	O
65	O
kg	O
,	O
respectively	O
)	O
.	O

Patient	O
performance	O
on	O
the	B-O
Logical	I-O
Memory	I-O
Test	I-O
,	O
Semantic	B-O
Word	I-O
Fluency	I-O
Test	I-O
,	O
Trail	B-O
Making	I-O
Test	I-O
,	O
Index	B-O
of	I-O
Independence	I-O
in	I-O
Activities	I-O
of	I-O
Daily	I-O
Living	I-O
,	O
Instrumental	B-O
Activities	I-O
of	I-O
Daily	I-O
Living	I-O
Scales	I-O
(	I-O
IADL	I-O
)	I-O
,	O
and	O
the	B-O
Physician	I-O
and	I-O
Caregiver	I-O
Clinical	I-O
Global	I-O
Impression	I-O
of	I-O
Change	I-O
(	I-O
CGIC	I-O
)	I-O
was	O
assessed	O
at	O
baseline	O
and	O
at	O
the	O
end	O
of	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
A	B-I
family	I-I
intervention	I-I
to	O
delay	O
nursing	O
home	O
placement	O
of	O
patients	B-P
with	I-P
Alzheimer	I-P
disease	I-P
.	O

A	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Randomized	O
controlled	O
intervention	O
study	O
.	O

Outpatient	O
research	O
clinic	O
in	O
the	O
New	O
York	O
City	O
metropolitan	O
area	O
.	O

Referred	B-P
,	I-P
volunteer	I-P
sample	I-P
of	I-P
206	I-P
spouse	I-P
-	I-P
caregivers	I-P
of	I-P
AD	I-P
patients	I-P
who	I-P
enrolled	I-P
in	I-P
the	I-P
study	I-P
during	I-P
a	I-P
3	I-P
1	I-P
/	I-P
2	I-P
-	I-P
year	I-P
period	I-P
.	O

All	O
patients	O
were	O
living	O
at	O
home	O
at	O
baseline	O
and	O
had	O
at	O
least	O
1	O
relative	O
living	O
in	O
the	O
area	O
.	O

Caregivers	O
in	O
the	O
treatment	O
group	O
were	O
provided	O
with	O
6	B-I
sessions	I-I
of	I-I
individual	I-I
and	I-I
family	I-I
counseling	I-I
within	O
4	O
months	O
of	O
enrollment	O
in	O
the	O
study	O
and	O
were	O
required	O
to	O
join	O
support	O
groups	O
.	O

In	O
addition	O
,	O
counselors	O
were	O
available	O
for	O
further	O
counseling	O
at	O
any	O
time	O
.	O

Time	B-O
from	I-O
enrollment	I-O
of	I-O
caregivers	I-O
in	I-O
the	I-O
study	I-O
to	I-O
placement	I-O
of	I-O
the	I-O
AD	I-O
patients	I-O
in	I-O
a	I-O
nursing	I-O
home	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
multicenter	O
double	O
-	O
blind	O
study	O
of	O
controlled	B-I
-	I-I
release	I-I
physostigmine	I-I
for	O
the	O
treatment	O
of	O
symptoms	O
secondary	O
to	O
Alzheimer	O
'	O
s	O
disease	O
.	O

Physostigmine	O
Study	O
Group	O
.	O

METHODS	O
:	O
During	O
dose	O
titration	O
,	O
subjects	O
received	O
18	B-I
,	O
24	B-I
,	O
or	O
30	B-I
mg	I-I
of	I-I
physostigmine	I-I
or	O
placebo	B-C
daily	O
.	O

After	O
a	O
2	O
-	O
week	O
washout	O
period	O
,	O
366	B-P
subjects	I-P
with	I-P
putative	I-P
improvement	I-P
were	O
randomized	O
to	O
receive	O
either	O
placebo	B-C
or	O
their	B-I
best	I-I
dose	I-I
of	I-I
physostigmine	I-I
in	O
a	O
6	O
-	O
week	O
double	O
-	O
blind	O
trial	O
.	O

Nonresponding	O
patients	O
(	O
439	O
)	O
were	O
randomized	O
to	O
receive	O
in	O
a	O
separate	O
double	O
-	O
blind	O
trial	O
either	O
placebo	B-C
or	O
their	B-I
highest	I-I
tolerated	I-I
dose	I-I
of	I-I
physostigmine	I-I
.	O

The	O
primary	O
efficacy	O
measures	O
included	O
the	B-O
cognitive	I-O
subscale	I-O
of	I-O
the	I-O
Alzheimer	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
(	I-O
ADAS	I-O
)	I-O
and	O
a	B-O
Clinical	I-O
Global	I-O
Impression	I-O
of	I-O
Change	I-O
(	I-O
CGIC	I-O
)	I-O
.	O

Secondary	O
measures	O
included	O
the	B-O
Mini	I-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
and	O
two	B-O
activities	I-O
-	I-O
of	I-O
-	I-O
daily	I-O
-	I-O
living	I-O
scales	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
tacrine	B-I
on	O
language	O
,	O
praxis	O
,	O
and	O
noncognitive	O
behavioral	O
problems	O
in	O
Alzheimer	O
disease	O
.	O

METHODS	O
:	O
An	O
exploratory	O
analysis	O
using	O
last	O
observation	O
carried	O
forward	O
.	O

The	O
study	O
population	O
included	O
a	B-C
placebo	I-C
group	O
(	O
n	O
=	O
181	O
)	O
and	O
all	O
patients	O
randomized	O
to	O
treatment	O
within	O
160	B-I
mg	I-I
/	I-I
d	I-I
of	I-I
tacrine	I-I
hydrochloride	I-I
(	O
n	O
=	O
234	O
)	O
,	O
regardless	O
of	O
highest	O
dose	O
achieved	O
or	O
duration	O
of	O
tacrine	B-I
therapy	I-I
.	O

Male	B-P
and	I-P
female	I-P
subjects	I-P
,	I-P
at	I-P
least	I-P
50	I-P
years	I-P
of	I-P
age	I-P
,	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
and	I-P
detectable	I-P
baseline	I-P
deficits	I-P
in	I-P
discrete	I-P
cognitive	I-P
and	I-P
noncognitive	I-P
parameters	I-P
.	O

Change	O
from	O
baseline	O
to	O
last	O
observation	O
carried	O
forward	O
in	O
discrete	B-O
subscale	I-O
scores	I-O
of	I-O
the	I-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
(	I-O
ADAS	I-O
)	I-O
:	O
cognitive	B-O
(	O
memory	B-O
,	O
language	B-O
,	O
praxis	B-O
)	O
and	O
noncognitive	B-O
(	O
mood	B-O
,	O
behavior	B-O
)	O
.	O

Improvement	O
was	O
defined	O
as	O
a	O
decrease	O
of	O
at	O
least	O
1	O
point	O
from	O
baseline	O
;	O
stabilization	O
was	O
defined	O
as	O
no	O
change	O
or	O
a	O
decrease	O
from	O
baseline	O
.	O

-DOCSTART-	O

Title	O
:	O
Metrifonate	B-I
benefits	O
cognitive	O
,	O
behavioral	O
,	O
and	O
global	O
function	O
in	O
patients	B-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
A	O
prospective	O
,	O
36	O
-	O
week	O
,	O
multicenter	O
,	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
parallel	O
group	O
study	O
of	O
metrifonate	B-I
in	O
probable	B-P
AD	I-P
patients	I-P
,	O
including	O
a	O
2	O
-	O
week	O
screening	O
period	O
,	O
a	O
26	O
-	O
week	O
double	O
-	O
blind	O
treatment	O
period	O
,	O
and	O
a	O
follow	O
-	O
up	O
visit	O
at	O
8	O
weeks	O
post	O
-	O
treatment	O
.	O

A	O
total	O
of	O
24	O
ambulatory	O
clinics	O
in	O
the	O
United	O
States	O
in	O
a	O
variety	O
of	O
settings	O
,	O
including	O
contract	O
research	O
organizations	O
,	O
public	O
health	O
facilities	O
,	O
and	O
universities	O
.	O

Patients	O
met	O
diagnostic	O
criteria	O
for	O
probable	O
AD	O
as	O
defined	O
by	O
the	O
work	O
group	O
of	O
the	O
National	O
Institute	O
for	O
Neurological	O
and	O
Communicative	O
Diseases	O
and	O
Stroke	O
and	O
the	O
Alzheimer	O
'	O
s	O
Disease	O
and	O
Related	O
Disorders	O
Association	O
.	O

Patients	O
had	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
scores	O
of	O
10	O
to	O
26	O
and	O
Ischemic	O
Scores	O
(	O
Rosen	O
Modification	O
)	O
of	O
<	O
4	O
.	O

A	B-P
total	I-P
of	I-P
408	I-P
patients	I-P
were	O
enrolled	O
.	O

Percentages	O
of	O
patients	O
completing	O
double	O
-	O
blind	O
treatment	O
were	O
88	O
%	O
and	O
79	O
%	O
in	O
the	B-C
placebo	I-C
and	O
metrifonate	B-I
groups	O
,	O
respectively	O
.	O

Rates	O
of	O
discontinuation	O
due	O
to	O
adverse	O
events	O
were	O
4	O
%	O
in	O
the	B-C
placebo	I-C
group	O
and	O
12	O
%	O
in	O
the	B-I
metrifonate	I-I
group	O
.	O

Placebo	B-C
or	O
metrifonate	B-I
was	O
administered	O
once	O
daily	O
.	O

Metrifonate	B-I
-	O
treated	O
patients	O
received	O
a	O
loading	O
dose	O
of	O
100	O
to	O
180	O
mg	O
based	O
on	O
weight	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
)	O
for	O
2	O
weeks	O
,	O
followed	O
by	O
a	O
maintenance	O
dose	O
of	O
30	O
to	O
60	O
mg	O
based	O
on	O
weight	O
(	O
0	O
.	O
65	O
mg	O
/	O
kg	O
)	O
for	O
24	O
weeks	O
.	O

Primary	O
efficacy	O
variables	O
were	O
the	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
Cognitive	I-O
Subscale	I-O
(	I-O
ADAS	I-O
-	I-O
Cog	I-O
)	I-O
and	O
the	B-O
Clinician	I-O
'	I-O
s	I-O
Interview	I-O
-	I-O
Based	I-O
Impression	I-O
of	I-O
Change	I-O
with	I-O
Caregiver	I-O
Input	I-O
(	I-O
CIBIC	I-O
-	I-O
plus	I-O
)	I-O
.	O

Secondary	O
efficacy	O
variables	O
included	O
the	B-O
Neuropsychiatric	I-O
Inventory	I-O
(	I-O
NPI	I-O
)	I-O
,	O
the	B-O
Disability	I-O
Assessment	I-O
in	I-O
Dementia	I-O
,	O
the	B-O
Global	I-O
Deterioration	I-O
Scale	I-O
(	I-O
GDS	I-O
)	I-O
,	O
the	B-O
ADAS	I-O
-	I-O
Noncognitive	I-O
subscale	I-O
(	I-O
ADAS	I-O
-	I-O
Noncog	I-O
)	I-O
,	O
the	B-O
MMSE	I-O
,	O
and	O
the	B-O
Clinician	I-O
'	I-O
s	I-O
Interview	I-O
-	I-O
Based	I-O
Impression	I-O
of	I-O
Severity	I-O
with	I-O
Caregiver	I-O
Input	I-O
(	I-O
CIBIS	I-O
-	I-O
plus	I-O
)	I-O
.	O

Outcome	O
measures	O
reflected	O
changes	O
from	O
baseline	O
at	O
week	O
26	O
for	O
all	O
variables	O
.	O

Safety	O
was	O
assessed	O
with	O
incidences	B-O
of	I-O
premature	I-O
termination	I-O
,	O
treatment	B-O
-	I-O
emergent	I-O
events	I-O
and	O
mortality	B-O
,	O
and	O
routine	B-O
safety	I-O
evaluations	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Caffeine	O
based	O
measures	O
of	O
CYP1A2	O
activity	O
correlate	O
with	O
oral	O
clearance	O
of	O
tacrine	B-I
in	O
patients	B-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
The	B-O
pharmokinetics	I-O
of	O
a	B-I
single	I-I
40	I-I
mg	I-I
oral	I-I
dose	I-I
of	I-I
tacrine	I-I
were	O
measured	O
in	O
19	B-P
patients	I-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

Each	O
patient	O
also	O
received	O
2	O
mg	O
kg	O
(	O
-	O
1	O
)	O
[	O
13	O
C	O
-	O
3	O
-	O
methyl	O
]	O
caffeine	O
orally	O
and	O
had	O
breath	O
and	O
urine	O
samples	O
collected	O
.	O

